Sen. John Boozman Sells Off Shares of Eli Lilly and Company (NYSE:LLY)

Senator John Boozman (R-Arkansas) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on December 08th, the Senator disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on November 21st.

Senator John Boozman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Tortoise North American Pipeline Fund (NYSEARCA:TPYP) on 11/21/2025.
• Sold $1,001 – $15,000 in shares of iShares Russell 2000 ETF (NYSEARCA:IWM) on 11/21/2025.
• Purchased $1,001 – $15,000 in shares of iShares CMBS ETF (NYSEARCA:CMBS) on 11/21/2025.
• Purchased $1,001 – $15,000 in shares of Goldman Sachs Access Investment Grade Corporate Bond ETF (NYSEARCA:GIGB) on 11/21/2025.
• Sold $1,001 – $15,000 in shares of iShares Core S&P 500 ETF (NYSEARCA:IVV) on 11/21/2025.
• Purchased $1,001 – $15,000 in shares of Janus Henderson Mortgage-Backed Securities ETF (NYSEARCA:JMBS) on 11/21/2025.
• Sold $1,001 – $15,000 in shares of Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA) on 11/21/2025.
• Purchased $1,001 – $15,000 in shares of iShares MBS ETF (NASDAQ:MBB) on 11/21/2025.
• Sold $1,001 – $15,000 in shares of FT Energy Income Partners Enhanced Income ETF (NYSEARCA:EIPI) on 11/21/2025.
• Sold $1,001 – $15,000 in shares of Vanguard Global ex-U.S. Real Estate ETF (NASDAQ:VNQI) on 11/21/2025.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $995.63 on Tuesday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The stock has a fifty day moving average price of $924.25 and a 200 day moving average price of $812.32. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The company has a market cap of $941.25 billion, a PE ratio of 48.71, a P/E/G ratio of 1.12 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. BMO Capital Markets set a $1,200.00 price target on shares of Eli Lilly and Company in a research note on Thursday. National Bankshares set a $1,286.00 price objective on Eli Lilly and Company in a report on Monday, December 1st. Leerink Partnrs raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Morgan Stanley raised their price target on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a report on Monday, November 24th. Finally, HSBC upped their price objective on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,087.32.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Brighton Jones LLC raised its position in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares during the last quarter. Kaufman Rossin Wealth LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at $242,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Eli Lilly and Company by 16.0% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 34,018 shares of the company’s stock valued at $28,096,000 after acquiring an additional 4,688 shares during the last quarter. Finally, Koss Olinger Consulting LLC purchased a new stake in Eli Lilly and Company during the 1st quarter worth about $388,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.